112 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Completed
Has Results
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212;   Drug: docetaxel
3 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
4 Active, not recruiting Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: bevacizumab;   Biological: recombinant interferon alfa
5 Not yet recruiting A Study of LY2835219 in Participants With Previously Treated Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: LY2835219;   Drug: Erlotinib
6 Active, not recruiting BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus;   Drug: BNC105P
7 Active, not recruiting Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: tamoxifen citrate;   Radiation: Radiation Therapy
8 Terminated BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
9 Active, not recruiting Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
10 Completed Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
11 Completed Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: letrozole
12 Recruiting Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Condition: Tumor Pathway Activations Inhibited by Dovitinib
Intervention: Drug: Dovitinib (TKI258)
13 Unknown  Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
14 Active, not recruiting A Study in Second Line Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab;   Drug: Irinotecan;   Biological: Placebo;   Drug: Folinic Acid;   Drug: 5-Fluorouracil
15 Active, not recruiting Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Radiation: radiation therapy;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
16 Active, not recruiting
Has Results
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab
17 Terminated Combination Chemotherapy in Treating Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Biological: filgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride
18 Active, not recruiting Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Bevacizumab [Avastin];   Drug: Paclitaxel;   Drug: Placebo
19 Active, not recruiting Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib;   Drug: Sorafenib
20 Active, not recruiting Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: prednisone

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years